Tempest reports 100% CR rate in REDEEM-1 trial; plans U.S. registrational study in 2026

Tempest Therapeutics, Inc.

100% complete response (CR) rate among all six efficacy-evaluable patients in REDEEM-1 trial of TPST-2003 in rrMM.
Favorable safety profile: no Grade ≥3 CRS or ICANS across dose levels in REDEEM-1.
Prior 24-patient IIT showed 89.5% CR rate and median progression-free survival of 23.1 months.
Tempest plans to submit U.S. IND and initiate registrational study of TPST-2003 in 2026, subject to clearance.
Company exploring TPST-2003 in LBCL; expects initial data from TPST-3003 and TPST-4003 programs later in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.